IONQ is trading up +6.35% at $45.24 during regular market hours, extending a +4.4% gain from the prior session's close of $42.54. Primary catalyst: IonQ announced the industry's first end-to-end real-time quantum error-correction decoder running on a single standard CPU.

LUNR reported Q2 2026 revenue of $206 million with a record $1.8 billion backlog driven by spacecraft and infrastructure contracts. RKLB posted Q2 2026 revenue of $234 million, up 62% year over year, with backlog reaching $2.36 billion across launch and space systems.

ETHA provides direct exposure to ether (ETH) through a passive grantor trust structure with a low 0.25% expense ratio, while SSK targets Solana (SOL) performance plus staking rewards through a more complex structure with a 0.75% expense ratio. ETHA holds essentially one primary asset (ether), offering pure price tracking, whereas SSK incorporates staking mechanisms and may allocate to related exchange-traded products for yield generation.

AEHR is a smaller, higher-growth semiconductor test and burn-in specialist that has surged sharply in recent months on AI-related demand, trading at a premium valuation. ONTO is a larger, profitable process-control leader with a record backlog and stronger, more diversified revenue base.

LUNR operates at a materially larger revenue scale, with a roughly $1.8 billion backlog versus VOYG 's record $275 million backlog. Both companies are tied to space and defense spending, but LUNR skews toward lunar infrastructure and satellite communications, while VOYG spans defense systems, space solutions, and commercial space stations.

DCX fell roughly -25.5% during regular trading, sliding to about $0.055 from a $0.0734 prior-session close, extending a multi-day collapse. Primary catalyst: the company announced a 160-for-1 reverse stock split (share consolidation) effective Sept. 28 to regain Nasdaq minimum bid-price compliance.

SFIX is down roughly -24% today, with the move starting in after-hours trading following its fiscal Q4 2026 report and extending through premarket and the regular session. The primary catalyst was weak guidance: fiscal 2027 revenue of $1.31B–$1.36B and Q1 revenue of $323M–$328M both came in well below analyst expectations, with management citing a "more challenging consumer environment."

RKDA is trading down roughly -22.5% to about $0.33 in the regular session, extending an after-hours/overnight slide from its $0.426 close on Sept. 23. The drop follows an extremely volatile Sept. 23 session, when about 25M shares traded versus a ~518K average in a $0.28–$0.68 range — a speculative, low-float spike now unwinding.

TWG shares are down roughly -27.2% intraday (~$0.196) during regular Nasdaq trading, after closing at $0.2696 on September 23. The decline reverses an overnight/after-hours surge that briefly pushed the stock above $0.49 on a positive FY26 profit alert (net profit guided +100% year-over-year).

Trio-Tech International (TRT) fell -20.96% to roughly $9.05 from a prior close of $11.45, with the decline occurring during regular trading hours. The semiconductor testing-services provider slid despite its recent move to the Nasdaq Global Market (Sept. 16), as an elevated trailing P/E near 294x left the low-float name vulnerable to selling.

NEOV shares fell -24.29% to about $2.40 in Thursday's regular session, extending a sharp after-hours decline following its Sept. 23 earnings release. The drop was triggered by a big fiscal Q4/FY2026 miss: EPS of -$0.24 versus a roughly -$0.07 to -$0.09 consensus, and revenue of just ~$13.5K against ~$2M expected.

ARTL is trading down about -32.83% intraday near $4.91 versus a $7.31 prior close, during the regular session. The decline is a sharp reversal after Wednesday's +76% close (+206% intraday) spike on its ART27.13 obesity-treatment patent filing.

VSA is down -29.95% to $2.55 during the regular session, reversing Wednesday's +83.84% surge that closed at $3.64. The decline is a retracement of a prior-session speculative spike that hit an intraday high of $7.12 on roughly 15.7M shares versus typical volume of only a few thousand.

IPDN fell about -36% in regular trading to roughly $3.47, down from the prior session's close of $5.42. The drop is a sharp giveback after Tuesday's +38.97% surge, which followed a +16% gain on Sept 22.

XXII is down -38.89% during regular trading to roughly $1.43, extending an after-hours slide that began after Wednesday's +29% surge to a $2.34 close. The move is driven by a report that the FDA and administration plan to fast-track authorization for newer tobacco products such as flavored vapes, threatening 22nd Century's status as the only FDA-authorized reduced-nicotine cigarette maker (VLN).

WHLR is trading down -45.22% to $2.98 during regular market hours, reversing the prior session's +190.91% surge to a $5.44 close. The decline is a sharp pullback/profit-taking after a 1-for-9 reverse stock split sparked extreme, speculative volatility, with split-adjusted trading beginning September 22.

BENF is down -51.03% to $1.42 in the regular session, giving back a large portion of the prior session's +438.73% surge to a $2.90 close. The selloff is primarily profit-taking after Wednesday's explosive rally, which was driven by a plan to eliminate roughly $130 million in disputed debt and ~$850 million in preferred equity tied to convicted former CEO Brad Heppner.

HVIIU units declined roughly 57% over the past 30 days, from about $10.78 to $4.63, with most of the move concentrated in late September. The decline is structural rather than an earnings-driven selloff: Hennessy VII completed its business combination with ONE Nuclear Energy on September 23, 2026, and the combined company now trades under the ticker ONEN .

Two different AI plays: BE sells on-site fuel-cell power for data centers, while ORCL builds the cloud infrastructure and databases those facilities run on. Momentum gap: BE has delivered triple-digit gains over the past year on surging AI power demand, whereas ORCL has fallen sharply from its record high despite strong revenue growth.

SRZN surged roughly +104.7% intraday to about $33, up from a $16.16 prior close, during regular Nasdaq trading. Buying was driven by news around its SZN-8141 program, a bifunctional Wnt agonist/VEGF antagonist antibody for diabetic macular edema (DME).